Thursday, January 25th 2018
09.00 Chairperson’s Opening Remarks
09.40 Characterization of ADME Properties of Novel Protein Therapeutics
- Cinthia Pastuskovas Senior Scientist, Amgen
- Next generation protein therapeutics are engineered in an attempt to improve the efficacy of monoclonal antibody therapeutics in the oncology setting.
- Designing multifunctional therapeutics for enhanced pharmacologic activity or improved target selectivity.
- Altering the targeting and/or activity of a molecule can concomitantly lead to novel and unanticipated ADME properties and pharmacokinetics for the therapeutic.
- Characterization of the stability and overall disposition of bispecific antibodies and antibody-cytokine fusion proteins to help guide engineering and selection of lead candidates.
10.10 Understand Preclinical Pharmacokinetics and ADME of Bispecific T-cell Engagers
- Dan Rock Executive Director, Amgen
- Bispecific T-cell engagers represent novel class of protein molecules wherein engineering efforts can impact pharmacokinetics and pharmacologic activity.
- Understand the importance of preclinical experimental design criteria for translation to the clinic.
10.40 Novel Bone Metastasis Models in Syngeneic and Humanized Mice
- Mari Suominen Research Director, Pharmatest
- Importance of tumor microenvironment
- Testing antitumor efficacy in bone metastasis models
- Immunotherapy and bone
10.40 Morning Refreshments
11.50 Strategies for Using Models In CAR T Cell Research and Development
- Rafael Ponce Sr. Director, Preclinical Sciences, Juno Therapeutics
- Optimizing your preclinical models for CAR T cell research and development
- Challenges involved when characterizing your preclinical models for Car T cell research
12.20 Utilization of Murine Breast Cancer Models in Preclinical Immuno-Oncology Pharmacology
- Dylan Daniel Director - Scientific Development, MI Bioresearch
- Pros and Cons of the 4T1 Mammary Cancer Model
- Characteristics of Alternative Syngeneic Breast Models
- Responses of a New Model to Checkpoint Inhibition and T Cell Costimulation
12.40 Optimizing Preclinical Models for The Development of T Cell Dependent Bispecific (TDBs) Antibody Therapies Targeting Solid Tumors
- Maria Hristopoulos Translational Oncology , Genentech
- Overview of TDB antibodies
- Limitations of using syngeneic and GEMM in vivo models to demonstrate antitumor
efficacy of TDBs in solid tumors
- Utilizing the huPBMC transfer model in NSG mice to demonstrate efficacy and
establish preclinical therapeutic index of TDB antibodies
13.10 Lunch and Networking
14.10 Multiplexing CAR T Cell Therapy
- Karen Spratt Research Scientist, Seattle Children’s
- Bispecific CARs targeting 2 antigens in ALL
- Multiplexing CAR with regulatory CARs
- How to track multiple CARs In Vitro and In Vivo
14.40 Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies & Immunotherapies
- Andrew Rhim CPRIT Scholar in Cancer Research, Associate Director for Translational Research , in Pancreatic Cancer Research, MD Anderson Cancer Center
- Describing models used and key considerations for experimental design
- Model responses and predictability of combination efficacy
15.10 Chairperson’s Closing Remarks
Close of the Annual Tumor Models San Francisco Summit
9.10 Transforming Translational Research: CANscript™ – A Better Predictive Model For Oncology
- Mark Paris Associate Director, Translational Applications Biopharma Business Development, Mitra Biotech Inc.
- Mitra Biotech has developed and clinically validated fully human ex-vivo platform technology (CANscript™)
- CANscript ™ uses patient material (tumor, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes
- This talk will explore how CANscript can better enable your translational efforts and aid in advancing your highest potential candidate into successful clinical trials